Lew JY, et al. (1999) Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity. Mol Pharmacol 55, 202-9 9927609

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S19-p - TH (rat) ▲

Modsite: KGFRRAVsEQDAKQA SwissProt Entrez-Gene Orthologous residues TH (human): S19‑p, TH iso2 (human): S19‑p, TH iso3 (human): S19‑p, TH iso4 (human): S19‑p, TH (mouse): S19‑p, TH (rat): S19‑p, TH (cow): S19‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma, pituitary cancer Relevant cell lines - cell types - tissues:  'brain, striatum', AtT20 (pituitary cell), PC-12 (chromaffin) Cellular systems studied:  tissue Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NSD-1015 no change compared to control butyrolactone no change compared to control butyrolactone, apomorphine no change compared to control nerve_damage increase cerbral hemitransection apomorphine inhibit treatment-induced increase butyrolactone increase apomorphine butyrolactone no effect upon treatment-induced increase no dose-dependent inhibition

S31-p - TH (rat) ▲

Modsite: KQAEAVTsPRFIGRR SwissProt Entrez-Gene Orthologous residues TH (human): S62‑p, TH iso2 (human): S58‑p, TH iso3 (human): S31‑p, TH iso4 (human): S35‑p, TH (mouse): S31‑p, TH (rat): S31‑p, TH (cow): S31‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma, pituitary cancer Relevant cell lines - cell types - tissues:  'brain, striatum', AtT20 (pituitary cell), PC-12 (chromaffin) Cellular systems studied:  tissue Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes okadaic_acid increase haloperidol increase nerve_damage no change compared to control cerebral hemitransection apomorphine no change compared to control NSD-1015 no change compared to control butyrolactone no change compared to control butyrolactone, apomorphine no change compared to control nerve_damage no change compared to control cerebral hemitransection apomorphine no change compared to control

S40-p - TH (rat) ▲

Modsite: RFIGRRQsLIEDARK SwissProt Entrez-Gene Orthologous residues TH (human): S71‑p, TH iso2 (human): S67‑p, TH iso3 (human): S40‑p, TH iso4 (human): S44‑p, TH (mouse): S40‑p, TH (rat): S40‑p, TH (cow): S40‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma, pituitary cancer Relevant cell lines - cell types - tissues:  'brain, striatum', AtT20 (pituitary cell), PC-12 (chromaffin) Cellular systems studied:  tissue Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NSD-1015 no change compared to control butyrolactone increase apomorphine butyrolactone inhibit treatment-induced increase nerve_damage increase cerbral hemitransection apomorphine inhibit treatment-induced increase